Anthony K Fung

This inventor holds 27 USPTO granted patents, primarily in Pharmaceutical Compounds. Top assignee: Abbott Laboratories Corporation. Active years: 1977-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony K Fung. Retrieved from https://idiyas.com/inventor/anthony-k-fung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27

% Patents Active = 100.0

Average Co-Inventor Count = 4.8

ph-index = 9

Forward Citations = 323(Granted Patents)

Location History:

Pierrefonds, CA (1977 - 1979)
Pierrefonds, CA (US) (1979)
Dollard Des Ormeaux, CA (1981)
Waukegan, IL (US) (1983 - 1991)
Gurnee, IL (US) (1993 - 1999)

Company Filing History:

27 out of 4,188

Abbott Laboratories Corporation

patents

Years Active: 1977-1999

Loading Chart...

Areas of Expertise:

Pyridone Antibiotic

Squalene Synthase Inhibitors

Protein Farnesyltransferase

Quinolizinone Compounds

Chiral Amino Compounds

Renin Inhibitors

Angiotensin II Receptor Antagonists

Non-Peptide Inhibitors

Isomerically Pure Compounds

Benzisoxazole Acids

Uricosuric Diuretic

Peptidylaminodiols

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5977133 - Pyridone antibiotic with improved safety profile (1999-11-02),

2. 5831115 - Inhibitors of squalene synthase and protein farnesyltransferase (1998-11-03),

3. 5783593 - Inhibitors of squalene synthetase and protein farnesyltransferase (1998-07-21),

4. 5726182 - Quinolizinone type compounds (1998-03-10),

5. 5668164 - Process for synthesis of chiral cis-and trans-3-amino-4 substituted (1997-09-16),

6. 5631401 - Inhibitors of protein farnesyltransferase and squalene synthase (1997-05-20),

7. 5618949 - Process for synthesis of chiral cis- and trans-3-amino-4-substituted (1997-04-08),

8. 5599816 - Quinolizinone type compounds (1997-02-04),

9. 5580872 - Quinolizinone type compounds (1996-12-03),

10. 5389647 - Renin inhibitors (1995-02-14),

11. 5342981 - Substantially isomerically pure hexane or hexene compounds (1994-08-30),

12. 5326776 - Angiotensin II receptor antagonists (1994-07-05),

13. 5268374 - Non-peptide renin inhibitors (1993-12-07),

14. 5250548 - Angiotensin II receptor antagonists (1993-10-05),

15. 5244910 - Renin inhibitors (1993-09-14),

Title: Innovations and Contributions of Anthony K Fung

Introduction

Anthony K Fung, an esteemed inventor based in Gurnee, IL, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 27 patents, Fung has demonstrated his expertise in developing innovative solutions for medical challenges.

Latest Patents

Among Fung's latest inventions is a pyridone antibiotic that promises an improved safety profile. This significant work involves antibacterial compounds characterized by specific formulas and their pharmaceutically acceptable salts, esters, and amides. These innovations are poised to enhance treatment options for bacterial infections. Another noteworthy patent encompasses inhibitors of squalene synthase and protein farnesyltransferase. This invention introduces a compound designed to inhibit farnesylation of the oncogene protein Ras and decrease squalene production, thereby influencing cholesterol biosynthesis.

Career Highlights

Anthony K Fung is associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His role has facilitated advancements in therapeutic treatments, particularly in antibiotic development and cancer research. Fung's consistent drive to innovate underscores his standing as a prominent figure in pharmaceuticals.

Collaborations

Fung has collaborated with notable colleagues such as Jacob J Plattner and Saul H Rosenberg, further enhancing the breadth and impact of his research. These partnerships reflect the collaborative spirit inherent in scientific research, fostering innovation and development in the pharmaceutical industry.

Conclusion

Anthony K Fung's contributions to pharmaceuticals through his numerous patents and collaborative efforts exemplify the vital role of innovation in addressing medical needs. His work continues to influence the landscape of healthcare, making significant strides in treatment methodologies.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]